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Abstract
Borna disease has been assessed according to the criteria of the Animal Health Law (AHL), in
particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of Borna disease
to be listed, Article 9 for the categorisation of Borna disease according to disease prevention and
control rules as in Annex IV and Article 8 on the list of animal species related to Borna disease. The
assessment has been performed following a methodology composed of information collection and
compilation, expert judgement on each criterion at individual and, if no consensus was reached before,
also at collective level. The output is composed of the categorical answer, and for the questions where
no consensus was reached, the different supporting views are reported. Details on the methodology
used for this assessment are explained in a separate opinion. According to the assessment performed,
Borna disease cannot be considered eligible to be listed for Union intervention as laid down in Article 5
(3) of the AHL because there was no compliance on criterion 5 A(v). Consequently, the assessment on
compliance of Borna disease with the criteria as in Annex IV of the AHL, for the application of the
disease prevention and control rules referred to in Article 9(1) is not applicable, as well as which
animal species can be considered to be listed for Borna disease according to Article 8(3) of the AHL.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on Borna disease (BD) according to the
criteria of the AHL articles as follows:
• Article 7: Borna disease proﬁle and impacts
• Article 5: eligibility of Borna disease to be listed
• Article 9: categorisation of Borna disease according to disease prevention and control rules as
in Annex IV
• Article 8: list of animal species related to Borna disease.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of BD according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Borna disease is a fatal neurological disorder ﬁrst described in horses and sheep and the name of
the disease is due to devastating epidemics in the end of the 19th century in horses in Borna, a town
in Saxony, Germany. The viral aetiology was already detected around 1925 and the underlying T-cell
mediated immunopathology was conﬁrmed in the 1980s. The family Bornaviridae belongs to the order
Mononegavirales, along with rhabdoviruses, ﬁloviruses and paramyxoviruses, which comprise single
stranded negative stranded and non-segmented RNA viruses. Within the family Bornaviridae, there is
only one genus Bornavirus and recent taxonomic classiﬁcation indicates at least ﬁve virus species.
Knowledge on Bornavirus infections has increased remarkably over the last decade and many
phylogenetically different viruses were detected using novel molecular methods. For instance, a variety
of novel bornaviruses was discovered in various avian and even reptile species and a novel virus with
proven zoonotic capacity was found in certain squirrel species. Moreover, integrated endogenous
sequences with homology to Bornavirus genes have been detected in several species and might
indicate a so far unknown innate antiviral strategy.
If necessary, data are split up according to the new taxonomic reorganisation of the family
Bornaviridae, order Mononegavirales, genus Bornavirus into at least ﬁve species (Mammalian 1
bornavirus, Mammalian 2 bornavirus, Psittacine 1 bornavirus, Psittacine 2 bornavirus, Passeriform 1
bornavirus, Waterbird 1 bornavirus, Passeriform 2 bornavirus, unassigned bornaviruses, Elapid 1
bornavirus, unclassiﬁed bornaviruses). For clarity, data for mammals, birds and other animals such as
reptiles are summed up whenever possible.
AHL assessment on borna disease
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3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
There are many reports on endogenous Bornavirus-like (EBL) sequences in many different animal
classes: (e.g. birds, mammals, reptiles, ﬁshes, insects and arachnids), infraclasses (e.g. marsupials)
superorders and orders (e.g. primates, rodents, chiroptera, carnivores and afrotheria), suborders (e.g.
serpents) or families (for instance, elephants, lemurs, squirrels and primates). Their role still remains
to be clariﬁed but might be associated with a novel type of antiviral immunity such as protection
against further Bornavirus infections (Belyi et al., 2010; Horie et al., 2010; Horie et al., 2013; Fujino
et al., 2014; Honda et al., 2016).
Reports on natural infection are based on varying detection methods, e.g. histological lesions,
presence of viral antigen and RNA or virus-speciﬁc serum antibodies and/or viral RNA only.
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): Reservoir bicoloured white-
toothed shrew, zoo animals (alpacas (Vicugna pacos), sloth (Bradypodidae, Megalonychidae), vari
monkeys (Varecia), hippopotamus (Hippopotamus amphibius)), animals kept in husbandries
(variegated squirrels (Sciurus variegatoides), Prevost’s squirrels (Callosciurus prevostii), one report on
lynx (unspeciﬁed) deer (unspeciﬁed) (D€urrwald and Ludwig, 1997; D€urrwald et al., 2006; Kinnunen
et al., 2007; Richt et al., 2007; Herden et al., 2013). Reports on naturally infected raccoons
(Procyon lotor) and macaques based on virus-speciﬁc serum antibodies and viral RNA detection in the
brain only also exist (Hagiwara et al., 2008; Hagiwara et al., 2009). Other wildlife species, e.g. foxes
(Vulpes vulpes), badgers (Meles meles) and small mammals can display also virus-speciﬁc serum
antibodies but no other signs of infection (Kinnunen et al., 2007; Bourg et al., 2013; Bourg et al.,
2016).
Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Animals kept in husbandry: psittacine birds
(e.g. order Psittaciformes at least 34 genera), canaries, ﬁnches (e.g. munia, estrildid ﬁnches),
pheasant (one case), wild birds: psittacines, waterbirds (e.g. Canada goose (Branta canadensis),
trumpeter swan (Cygnus buccinator), mute swan (Cygnus olor), gulls, wild ducks (e.g. northern
pintail (Anas acuta), gadwall (Anas strepera), mallard (Anas plytyrhynchos), bald eagle
(Haliaeetus lecuocephalus) (Staeheli et al., 2010; Heffels-Redmann et al., 2011; Payne et al., 2012;
Delnatte et al., 2013; Herden et al., 2013; Rubbenstroth et al., 2013; Delnatte et al., 2014b; Encinas-
Nagel et al., 2014; Guo et al., 2014; Rubbenstroth et al., 2014b; Bourque et al., 2015; Kuhn et al.,
2015). For ducks, cranes, gulls, haliaeetus and emberiza data on natural infection based on detection
of viral RNA only also exist (Sassa et al., 2015).
Bornaviruses in reptiles (only sequences reported so far): Loveridge’s garter snake
(Elapsoidea loveridgei), Gaboon viper (Bitis gabonica) (Stenglein et al., 2014; Kuhn et al., 2015).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Mammalian bornaviruses (Mammalian 1 bornavirus): Main natural hosts (or accidental
hosts) are horses and sheep. Natural infections have also been described in other Equidae, farm
animals (cattle, goats), rabbits, and very rarely in companion animals (dog, cat) (Rott and Becht,
1995; Staeheli et al., 2000; D€urrwald et al., 2006; Kinnunen et al., 2007; Herden et al., 2013).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Mammalian bornaviruses: so far shown for bank voles (Myodes glareolus) (Kinnunen et al.,
2011).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Mammalian bornaviruses (Mammalian 1 bornavirus): Very broad host range for
experimental infections ranging from chicken up to non-human primates (e.g. tree shrew, rhesus
monkey, chicken, rat, mouse, hamster, gerbil, rabbit, guinea pig (Heinig, 1969; Rott and Becht, 1995;
Staeheli et al., 2000; Herden et al., 2013). Experimental Infection of ferrets, pigeons, dogs, and
hamsters did not result in clinical disease but usually persistent infection (Danner, 1982; Rott and
Becht, 1995).
Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform 1 bornavirus):
psittacines, e.g. cockatiels, african grey parrots, patagonian conures as well as canaries; failed in ducks
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in one study (Gancz et al., 2009; Gray et al., 2010; Staeheli et al., 2010; Piepenbring et al., 2012;
Rubbenstroth et al., 2013; Piepenbring et al., 2016).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
Mammalian bornavirus (Mammalian 1 bornavirus): bicoloured white-toothed shrew (Hilbe
et al., 2006; Bourg et al., 2013; D€urrwald et al., 2014; Nobach et al., 2015). It needs to be further
investigated whether variegated squirrels or Prevost’s squirrels serve as reservoir for the novel
variegated squirrel 1 bornavirus (VSBV-1).
Avian bornaviruses: Unknown whether susceptible wild animals serve as reservoir, especially wild
birds.
Parameter 6 – Domestic reservoir species (or family/orders)
Mammalian bornavirus (Mammalian 1 bornavirus): unknown
Avian bornaviruses: unknown
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
Mammalian bornaviruses (Mammalian 1 bornavirus): most data are available for horses with
some data also on cattle and sheep. Clinical neurological disease occurs typically in endemic areas in
Germany, Switzerland, Austria and Liechtenstein. Due to reports on clinical disease in other countries,
possible other clinical signs associated with infection and detection of virus-speciﬁc serum antibodies
as well as/or viral RNA, within Europe and outside Europe, e.g. France, Sweden, Finland, Italy, Turkey,
Israel, Japan, Iran, China, Australia and the USA, a more widespread distribution has been discussed
but still awaits ﬁnal proof or disproof by detailed epidemiological and phylogenetic studies (Herden
et al., 2013). For instance, a case of BD in a horse in Great Britain could be traced back to infection in
a German endemic area (Jacobsen et al., 2010). However, the continuous detection of novel
Bornaviruses or related viral sequences might contribute to assess the geographical distribution of
different bornaviruses in the future.
BD was epidemic at the end of the 19th century, but the incidence decreased signiﬁcantly up to the
1990s. The great majority of infections is characterised by a clinically inapparent course, and disease
incidence is typically low despite the higher seroprevalence in horses, even in endemic areas. In
endemic areas in Germany (Bavaria), the incidence dropped down to about 0.02–0.04% in the 1990s
(Herden et al., 2013). Thus, the incidence of clinical BD is relatively low, with less than 100 affected
horses or sheep per year in endemic areas (Herzog et al., 1994; D€urrwald and Ludwig, 1997; Caplazi
et al., 1999; Staeheli et al., 2000; Muller-Doblies et al., 2004; D€urrwald et al., 2006; Richt et al., 2007;
Kistler et al., 2010). Seasonally, there is an increase of clinical cases in spring and early summer and
secular rhythm has also been observed with disease peaks every 3–5 years. Species wise, the highest
incidence of clinical disease is in horses and donkeys (less than 0.1.% of horse population in second
half of 20th century), lower in sheep (with less than 0.01% of sheep population in second half of 20th
century), even lower in new world camelids, other herbivores and rare in carnivores, e.g. dogs
(Staeheli et al., 2000; D€urrwald et al., 2006).
It should be noted that seroepidemiological surveys from Germany indicate that infections in horses
and sheep can be inapparent. Clinically healthy horses in Germany display an average seroprevalence
of 11.5% (Herzog et al., 1994). However, seroprevalence increases in endemic areas up to 50% in
stables where clinically diseased horses had been detected (Grabner et al., 2002). Occurrence of
clinical disease is higher in stables with lower hygiene standards and mixed equine, bovine and ovine
population (Staeheli et al., 2000; D€urrwald et al., 2006).
Thus, there is a great difference between seroprevalence and the low incidence of clinical cases. It
has been speculated that various host and viral factors inﬂuence the outcome of the infection, e.g.
age, immune status and genetic background, virus strain and dose of infection (Herden et al., 2013).
Current expanding knowledge on the potential role of the endogenous bornaviral elements (see above)
might suggest additional mechanisms.
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Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform 1 and 2 bornavirus,
waterbird 1 bornavirus): Many different studies indicate that avian bornavirus (ABV) infections
occur worldwide (e.g. various European countries, e.g. Germany, Austria, Switzerland, Hungary, Spain,
Italy, the UK, Denmark, Canada, USA, Australia, Brazil, Japan) (Staeheli et al., 2010; Payne et al.,
2011a; Herden et al., 2013; Sassa et al., 2013; Encinas-Nagel et al., 2014; Guo et al., 2014;
Philadelpho et al., 2014; Sassa et al., 2015).
The typical clinical disease, proventricular dilatation disease (PDD) is associated with detection of
ABV infection in 60–100% of cases depending on the respective study but infection can also be found
in apparently clinically healthy animals (Herden et al., 2013).
Due to the large number of studies investigating the presence of ABV infections in captive and wild
birds, only selected data are further detailed.
In a study employing 1,442 live and 73 dead birds of 54 genera of psittaciformes from different
European countries (Germany, Spain, Italy, the UK, Denmark), ABV infection was detected in 22.8% of
animals with a coincidence of virus-speciﬁc serum antibodies and viral RNA in cloacal and crop swabs
in only 20% (Heffels-Redmann et al., 2012). This was conﬁrmed by a study testing 112 pet psittacines
in Brazil with a presence of 28.6% positive animals (Philadelpho et al., 2014). This coincides with a
study investigating 86 wild psittacines in Brazil with a detection rate of 30.2% (Encinas-Nagel et al.,
2014). A wide distribution of avian bornaviruses was also found in canary ﬂocks in a percentage of
40% (12/30 ﬂocks) and 22% of canaries tested, whereas the presence was lower in captive ﬁnches
(3/286 samples positive) (Rubbenstroth et al., 2013; Rubbenstroth et al., 2014b). In contrast, in Japan
in 2,078 samples from wild birds (1,908 waterfowl), only in 0.9% viral RNA was found (Sassa et al.,
2015) and in 4/93 (4.3%) of the investigated pet birds (Sassa et al., 2013). In waterfowl, distinct
avian bornaviruses (aquatic bird bornavirus 1) are widespread in North America and Canada in a
percentage ranging between 10% and 30%, reported as high as 50% in few studies, e.g. in Canada
geese, trumpeter and mute swans and ducks. They have been found in apparently healthy animals but
also in birds from Canada and North America (Payne et al., 2011a; Delnatte et al., 2013; Delnatte
et al., 2014b; Guo et al., 2014) with typical clinical or histopathological lesions. For instance, 24/409
(5.9%) geese samples were positive for viral RNA and in 51/995 (5.1%) geese necropsy cases from
Canada viral RNA was detected or in 78–88% of retrospectively selected cases based on clinical history
suggestive of avian borna virus infection (Payne et al., 2011a; Delnatte et al., 2013). Recently, aquatic
bird bornavirus (ABBV-1) was detected in 7/333 (2.1%) brains of apparently healthy geese originating
from Denmark (Thomsen et al., 2015).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Mammalian bornaviruses (Mammalian 1 bornavirus): Typically, in case of development of
clinical disease, natural Borna disease virus (BDV) infection in horses cause death 1–4 weeks after
onset of signs in 80–90% of animals (Schmidt, 1952; Grabner and Fischer, 1991; D€urrwald and
Ludwig, 1997; Grabner et al., 2002; Richt et al., 2007). In 72% of horse herds with BD cases, only
individual animals develop clinical manifest BD. In cattle and sheep, death occurs after 1–6 weeks or
1–3 weeks in more than 50% of animals, respectively (Richt et al., 1997b; Bode et al., 2001). In sheep
ﬂocks, it has been reported that large animal numbers can be affected. In horse stables, repeated
outbreaks of BD can occur, typically some time ranging from 2 months up to several years after the
initial BD cases.
Avian bornaviruses (Psittacine bornavirus 1, Passeriform 1 and 2 bornavirus, waterbird
1 bornavirus): Many studies have shown that infection with ABV can run many different clinical
courses and infection status, either in natural or experimental infections. Signs might range from
typical PDD with gastrointestinal and/or neurological signs, sudden death, clinically inconspicuous so
that the morbidity rate is difﬁcult to assess (Herden et al., 2013). Thus, only few examples are given.
In a ﬁeld study monitoring 63 psittacines over a period of 1 year, four different groups of infected
and one group consisting of non-infected birds were classiﬁed. Only one group comprised clinical 6/63
(9.5%) PDD cases with various courses of virus infection whereas all other animals were subclinically
infected and were grouped together according to the presence of serum antibodies and/or viral RNA
(Heffels-Redmann et al., 2012). In experimental trials with cockatiels 5/18 (27.8%) or 12/18 (66.7%),
birds developed clinical signs depending on the viral genotype used (Piepenbring et al., 2012;
Piepenbring et al., 2016). Canaries and wild birds can also be infected without clinical signs or could
present typical clinical disease or histological lesions (Weissenb€ock et al., 2009; Payne et al., 2011a;
Payne et al., 2012; Delnatte et al., 2013; Rubbenstroth et al., 2013; Guo et al., 2014).
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Mortality
Parameter 3 – Case-fatality rate
Mammalian bornaviruses (Mammalian 1 bornavirus): Typically, natural BDV infection in
horses that develop clinical signs leads to death 1–4 weeks after onset of signs in 80–90% of animals
(Schmidt, 1952; Grabner and Fischer, 1991; D€urrwald and Ludwig, 1997; Richt et al., 1997b; Grabner
et al., 2002). In cattle and sheep, death was noted after 1–6 weeks or 1–3 weeks in more than 50%
of animals, respectively (Bode et al., 1994; Richt et al., 1997b).
Avian bornaviruses (Psittacine bornavirus 1, Passeriform 1 and 2 bornavirus, waterbird 1
bornavirus): For variability of clinical course and outcome of infection, refer to as case morbidity rate.
After ABV infection, sudden death might occur. The clinical picture of PDD has been described long before
the virus was detected so that former reports on PDD exist describing a mortality rate of 100%
(R-Gregory et al., 1994). In most cases, animals with overt clinical disease affected birds die due to
energy deﬁciency or have to be euthanised (Hoppes et al., 2010; Lierz et al., 2010; Herden et al., 2013).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
Mammalian bornaviruses (Mammalian 2 bornavirus): There are three conﬁrmed human
deaths between 2011 and 2013 in breeders of variegated squirrels (Sciurus variegatoides) infected
with novel bornavirus variegated squirrel 1 bornavirus (VSBV 1) belonging to the new species
mammalian 2 bornavirus (Hoffmann et al., 2015; Schlottau et al., 2017), technical note 2016.
Mammalian bornaviruses (Mammalian 1 bornavirus): There was a long and controversial
discussion whether the classical mammalian bornavirus BoDV-1 has to be regarded as zoonotic or not
and might be involved in certain human psychiatric syndromes, including e.g. major depressive
disorder, bipolar disorder, schizophrenia and autism. Some reports also described an association with
chronic fatigue syndrome, AIDS encephalopathy, multiple sclerosis, motor neuron disease and brain
tumours or the detection of viral RNA in peripheral blood mononuclear cells (PBMCs) and brain
(Herden et al., 2013). Sequence homology of the human BoDV-sequences with BoDV laboratory strains
or ﬁeld isolates handled in the respective laboratories could argue for potential cross-contamination at
laboratory level (Richt et al., 1997a; Schwemmle et al., 1999; D€urrwald et al., 2007). A recent large
cohort study in the USA also did not provide any evidence for bornavirus infection in psychiatric
patients (Hornig et al., 2012). However, it has been shown that psychiatric patients can exhibit virus
speciﬁc antibodies, but typically with low titres and avidity (Bechter et al., 1996; Billich et al., 2002;
Schwemmle and Billich, 2004).
Thus, it has to be emphasised that the VSBV-1 infection in humans was clearly different from the
data on an association of the classical BoDV with human diseases. In all three patients, high VSBV-1
RNA and antigen loads and serum titers were present substantiating that VSBV-1 is a quite different
novel zoonotic pathogen (Hoffmann et al., 2015).
Avian bornaviruses (Psittacine bornavirus 1, Passeriform 1 and 2 bornavirus, waterbird
1 bornavirus): There are no indications that avian bornaviruses are zoonotic in nature.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
Mammalian bornaviruses (Mammalian 1 bornavirus): As current knowledge, no resistant
strain to laboratory antiviral strategies has been reported. In this respect it should be noted that no
curative treatment exists so far, but many studies tried antiviral treatments in vitro or in vivo and could
show either reduction in viral loads, inhibition of viral spread.
Thus no curative treatment is available to date.
Avian bornaviruses: No resistant strain described so far.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
As of current knowledge, mammalian and avian bornaviruses are able to cause persistent
non-cytolytic infection in their respective hosts and cell culture systems. However, virus distribution can
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differ with widespread viral dissemination in nearly every organ system in reservoir species, variegated
squirrels or neonatally immune incompetent or immunocompromised rats. Virus distribution can be
highly variable in infected birds with similar widespread dissemination or more pronounced tropism to
the nervous system and gastrointestinal tract (Herden et al., 2013). In end hosts/accidental hosts,
typically a persistent infection with neurotropism occurs affecting the nervous system only.
Parameter 1 – Duration of infectious period in animals
Mammalian bornaviruses (Mammalian 1 bornavirus): Unknown for naturally infected
animals, for bicoloured white-toothed shrews viral shedding has been shown over 600 days in
husbandry (Nobach et al., 2015). Neonatally persistently infected rats also shed virus in urine, nasal
and lacrimal secretions (Narayan et al., 1983a,b; Sauder and Staeheli, 2003). The incubation period for
natural BD is unknown but a period ranging from 2 weeks to several months was proposed (Schmidt,
1912, 1952; Ludwig et al., 1985; Rott and Becht, 1995).This was underscored by naturally infected
animals, a horse in the UK and an alpaca in Germany which both had been infected in endemic areas
before being transported to the new region where they developed clinical signs, approximately
3–4 months later (Jacobsen et al., 2010; Priestnall et al., 2011). Experimentally, in rats, persistent
infection has also been shown over long periods for more than 210 days (Narayan et al., 1983a,b).
Avian bornaviruses (Psittacine bornavirus 1, Passeriform bornavirus 1): Only few
examples illustrating the situation are given.
In experimentally infected cockatiels either with PaBV2 oder PaBV4 infection was persistent until
the end of the investigation, e.g. up to 231 dpi (Gancz et al., 2009; Gray et al., 2010; Kistler et al.,
2010; Mirhosseini et al., 2011; Piepenbring et al., 2012; Piepenbring et al., 2016; Olbert et al., 2016).
In canaries, experimental infection was also persistent over 5 months (Rubbenstroth et al., 2013). The
reported incubation period of ABV infections is variable, ranging between approximately 20–60 days up
to 200 days (Gancz et al., 2009; Gray et al., 2010; Payne et al., 2011b; Piepenbring et al., 2012;
Piepenbring et al., 2016) in experimental trials.
Parameter 2 – Presence and duration of latent infection period
No data on latent infection, only subclinical courses have been described for ABV infections, e.g.
detailed in (Heffels-Redmann et al., 2011).
Parameter 3 – Presence and duration of the pathogen in healthy carriers
Mammalian bornaviruses (Mammalian 1 bornavirus): See also under susceptible animal
species, reservoir species.
So far known reservoir species bicoloured white-toothed shrew (Crocidura leucodon) for classical
mammalian virus BoDV-1 appear clinically inconspicuous (Nobach et al., 2015). Interestingly,
variegated squirrels (Sciurus variegatoides) infected with the novel VSBV-1 also do not show clinical
signs (Schlottau et al., 2017). Data from seroepidemiological surveys also indicates that infection can
be inapparent in horses and sheep (see also under prevalence/incidence).
Avian bornaviruses (Psittacine bornavirus 1, Passeriform bornavirus 1): Clinically
apparently healthy birds have been described for natural infection and after experimental inoculation
of psittacines and canaries and also for the panel of susceptible water birds, e.g. geese, swans, ducks,
gulls (see also Section 3.1.1.1) (Staeheli et al., 2010; Heffels-Redmann et al., 2011; Heffels-Redmann
et al., 2012; Payne et al., 2012; Herden et al., 2013; Rubbenstroth et al., 2013). Moreover, clinically
healthy animals with continuous or intermittent shedding of viral RNA occur.
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Most data are available for the classical mammalian Bornavirus BoDV-1.
Mammalian bornaviruses (Mammalian 1 bornavirus): Incubation at 37°C or storage in
serum for 24 h reduces infectivity only slightly. By storage at 4°C, BDV infectivity has been shown to
be stable for more than 3 months. Viral infectivity is more preserved in tissues and cell free virus
preparations than in cell culture extracts. Virus suspension stored at 80°C for 25 years was
successfully used for experimental infections. Dried preparations retain their infectivity also very long,
at room temperature for more than 2 month and under vacuum also for several years (Zwick, 1939;
Ludwig et al., 1973; Ludwig et al., 1988; Danner and Mayr, 1979; Herden et al., 2013).
AHL assessment on borna disease
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2017;15(7):4951
The virus resists acidic and alkaline milieu but neutral pH the best (Elford and Galloway, 1933;
Heinig, 1955; Danner and Mayr, 1979).
Virus inactivation can be achieved by heating to 56°C for longer than 3 h and the virus is labile at
pH 3. Since BoDV is an enveloped virus, common disinfection procedures for enveloped viruses can be
applied, e.g. UV light, acidic settings with a pH below 4 as well as lipid solvents such as ether,
chloroform or acetone or detergents (Danner, 1982; Herden et al., 2013).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): For natural infection of end
hosts/accidental hosts, intranasal infection via the olfactory pathway was assumed as the most likely
route of entry for a long time (Morales et al., 1988; Bilzer et al., 1995; Sauder and Staeheli, 2003;
Herden et al., 2013). Neonatally infected rats develop a disseminated virus infection with shedding of
infectious virus via secretions, urine and faeces (Morales et al., 1988; Bilzer et al., 1995; Sauder and
Staeheli, 2003). This resembles closely the situation in the naturally infected reservoir, the bicoloured
white-toothed shrew where infectious virus was also detected in secretions, excretions and skin
(Nobach et al., 2015). For the novel bornavirus, VSBV-1 a similar viral distribution was found
(Hoffmann et al., 2015; Schlottau et al., 2017). It can therefore be assumed that these ways of
shedding can serve as most likely transmission matrix. For transmission of virus from shrew to horses
contaminated food was also considered (Bourg et al., 2013).
Experimentally, various infection routes were successfully applied in rats, e.g. intranasal,
intracerebral, intraocular, intraperitoneal, foot pad infection, but not intravenous (Carbone et al., 1987;
Morales et al., 1988; Herden et al., 2013). The distance of the inoculation site to the central nervous
system (CNS) delayed onset of clinical disease (Carbone et al., 1987). Detection of viral RNA in PBMCs
has been reported but questioned by others (Herden et al., 2013) but viremia seem not to be involved
in viral spread which is substantiated that intravenous inoculation was not successful.
Only few data exist on potential vertical transmission in horses (Hagiwara et al., 2000) or in mice
(Okamoto et al., 2003).
Avian bornaviruses (Psittacine bornavirus 1, Passeriform bornvirus 1): For natural
infection, the horizontal orofaecal route has been assumed as most likely way of entry due to
detection of ABV RNA in faeces, cloacal and crop swabs. This has yet not been proven by respective
experimental trials. Experimentally infection was successful via various routes, e.g. intracerebral,
intravenous, subcutaneous, intramuscular or combination thereof but so far not oronasally (Gancz
et al., 2009; Gray et al., 2010; Kistler et al., 2010; Mirhosseini et al., 2011; Rubbenstroth et al., 2013;
Rubbenstroth et al., 2014a; Olbert et al., 2016; Piepenbring et al., 2016; Heckmann et al., 2017).
Recent phylogenetic data indicate that horizontal inter species transmission seem to be relatively
frequent as shown for PaBV2 and PaBV4 (Rubbenstroth et al., 2016). Horizontal transmission after
hatch has also been discussed as mode of transmission (Kerski et al., 2012).
ABV antigen has been detected in testes and ovaries of infected parrots (Raghav et al., 2010) so
that potential vertical transmission was assumed. To date, viral RNA was found in eggs, embryos
hatchlings of, e.g. different psittacine species, canaries, geese originating from infected parents (Lierz
et al., 2011; Kerski et al., 2012; Monaco et al., 2012; Rubbenstroth et al., 2013; Delnatte et al.,
2014a). It was speculated that ABV reach eggs either from penetration of the shell after egg
contamination, or contamination of oviduct secretions or ABV infection of ova or sperm (Monaco et al.,
2012). However, productive viral replication has not been demonstrated from eggs or embryos so far.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): To date, the classical
mammalian bornavirus has not been considered as a proven zoonotic pathogen.
The route of transmission from the variegated squirrels infected with VSBV-1 to the three human
cases remains to be elucidated but possibilities of intranasal infection, bites or scratches have been
hypothesised (Hoffmann et al., 2015).
Avian Bornaviruses: There are yet no indications that avian bornaviruses are zoonotic in nature.
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Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): No data on the incidence and
speed of transmission are yet available for the currently known reservoir population, the bicoloured
white-toothed shrews. Incidence of transmission from shrew to accidental/end hosts such as horses is
also unknown, the discrepancy between seroprevalence and clinical manifest disease which occur only
in single animals is detailed under morbidity. Data on the presence of viral antigen or RNA in peripheral
organs or secretions of end/accidental hosts are contradictory (Bilzer et al., 1995; Lebelt and Hagenau,
1996; Schmahl et al., 1999) but transmission between end/accidental hosts does not seem to play an
important role. This can be substantiated by the occurrence of only single diseased animals in one ﬂock
despite a high seroprevalence in stables with clinical manifest BD. See Section 3.1.1.2 Parameter 2.
Avian bornaviruses (Psittacine bornavirus 1, Passeriform bornvirus 1): By experimental
trials, in sentinel birds viral RNA might be detected or no contact transmission was noted (Piepenbring
et al., 2012; Rubbenstroth et al., 2013; Rubbenstroth et al., 2014a; Piepenbring et al., 2016). It has
been assumed that asymptomatic carriers might contribute to the perpetuation of ABV infections.
Interestingly, birds might not become infected despite close contact to ABV-infected birds (Raghav
et al., 2010; Heffels-Redmann et al., 2012; Rubbenstroth et al., 2014a).
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Assessment of R0 for infection either with mammalian bornaviruses or avian bornaviruses has not
been possible to date. The infection runs a completely different course in reservoir species or
immunocompromised/immune incompetent animals or accidental hosts. Variety of clinical signs and
infection are even more variable for avian bornaviruses, e.g. close-contact animals are not necessarily
infected (Rubbenstroth et al., 2014a; Bourque et al., 2015).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
Mammalian bornaviruses (Mammalian 1 bornavirus): There are endemic areas in Germany,
Austria, Switzerland and Liechtenstein (D€urrwald and Ludwig, 1997; Staeheli et al., 2000; Kolodziejek
et al., 2005; D€urrwald et al., 2006) where clinically diseased end hosts occur. For the classical BoDV-1,
endemic viral clusters with a strong geographical association have been reported being related to the
occurrence of the viral reservoir (Kolodziejek et al., 2005; D€urrwald et al., 2006; Hilbe et al., 2006;
Bourg et al., 2013; D€urrwald et al., 2014).
For seasonality and open questions on geographical distribution, see also under Section 3.1.1.2
Parameter 2.
Avian bornaviruses (Psittacine bornavirus 1, Passeriform bornavirus 1): Due to the
variability of courses of ABV infections (e.g. clinically healthy, PDD, sudden death, feather pecking) and
lack of association between presence of clinical signs and detection of ABV, the type of epidemiological
occurrence cannot be properly assessed.
Risk of introduction
Parameter 3 – Routes of possible introduction
Mammalian bornaviruses (Mammalian 1 bornavirus): Spread occurs most likely from
reservoir (white-toothed bicoloured shrews) to end/accidental host (e.g. horses) probably via
contaminated food and intranasal infection (Bourg et al., 2013; D€urrwald et al., 2014; Nobach et al.,
2015).
Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): For captive animals, trade or introduction of
new animals into husbandry without proper testing might contribute to viral introduction. Recently, a
lack of geographical association of viral sequences from captive psittacines might argue for assumed
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worldwide viral distribution by trade in the past (Rubbenstroth et al., 2016). In this respect, especially
clinically inconspicuous animals can represent potential risk factors (Herden et al., 2013). Whether or
how an introduction from wild birds to captive birds play a role remains yet unknown (Rubbenstroth
et al., 2016). For waterbirds, distinct geographical clusters of ABBV-1 in North America and Europe
have been described but dispersal areas are larger (Payne et al., 2012; Delnatte et al., 2013; Thomsen
et al., 2015; Rubbenstroth et al., 2016).
Parameter 4 – Number of animal moving and/or shipment size
Not applicable.
Parameter 5 – Duration of infectious period in animal and/or commodity
See under Section 3.1.1.5.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
There are no control measures in place so far.
Parameter 7 – Presence and duration of latent infection and/or carrier status
See under Section 3.1.1.5 Parameter 2.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): Most studies concerning
diagnostic tools exist for the classical mammalian bornavirus BoDV-1.
Diagnostic tools can either be applied for intra vitam or post-mortem diagnostics (Herden et al.,
2013). Viral infection can be diagnosed by the presence of virus speciﬁc antibodies in the serum and/or
cerebrospinal ﬂuid (CSF) (Grabner and Fischer, 1991; Grabner et al., 2002) and/or infectious virus, viral
antigens or RNA in the CNS post-mortem. Established test systems for serology are Western blot analysis
(Herzog et al., 1994; Herzog et al., 2008), enzyme-linked immunosorbent assay (ELISA) or indirect
immunoﬂuorescence assay (IFA) (Herzog and Rott, 1980; Grabner and Fischer, 1991; Herzog et al.,
1994; Grabner et al., 2002; Herzog et al., 2008; Bode et al., 2001). The IFA has been proven as test
system with a high sensitivity and speciﬁcity (Herzog et al., 2008). It should be mentioned that titres do
not correlate with the clinical course of the infection (Grabner et al., 2002; Herzog et al., 2008). Liquor
cerebrospinalis (CSF) investigation is also possible, e.g. cell count, biochemical analysis. There was a
debate on the presence of viral RNA or antigen in PBMC or leukocytes or even circulating immune
complexes (Nakamura et al., 1995; Bode et al., 2001; Dieckh€ofer, 2008) because the data could not be
reproduced in other studies (Grabner et al., 2002; Wolff et al., 2006; Herzog et al., 2008). However, viral
RNA might be detected from cells of the CSF.
Reliable intra vitam results in an animal displaying neurological signs are presence of virus speciﬁc
antibodies in the serum and/or CSF, CSF pleocytosis or seroconversion. However, it should be
mentioned that false negative serological results can occur in peracute or very early stages of acute
BD or also after treatment with corticosteroids (Grabner et al., 2002), and that clinically healthy horses
can be seropositive, usually without antibodies in the CSF (Herzog et al., 1994; Grabner et al., 2002).
In such cases and cases with viral speciﬁc serum antibodies, a post-mortem investigation is required
for a ﬁnal diagnosis (Herzog et al., 2008).
Post-mortem diagnosis of bornavirus infection is possible by various methods, e.g. histopathology,
demonstration of viral antigens or RNA by morphological methods (immunohistochemistry (IHC), in situ
hybridisation (ISH)), western blot (WB), various reverse transcription polymerase chain reaction (RT-PCR)
and real time RT approaches (Bilzer et al., 1996; Herden et al., 1999; Grabner et al., 2002; Porombka
et al., 2008; Werner-Keiss et al., 2008; Herden and Richt, 2009; Herden et al., 2013; Bourg et al., 2016).
There was a 100% overlap for histopathological lesions (non-purulent meningoencephalitis), IHC, WB
and nested RT-PCR in equine cases of acute BD using more than 150 horses with or without BD (Herden
et al., 1999; Grabner et al., 2002). With fresh tissue material, isolation of infectious virus is also possible
(Herden et al., 1999; Herden et al., 2000; Nobach et al., 2015).
For the novel VSBV-1, also reliable methods have been established comparable to the ones used for
BoDV-1, e.g. IFA, IHC, RT-PCR and real time RT PCR assays and isolation of infectious virus (Hoffmann
et al., 2015; Schlottau et al., 2017).
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Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Diagnostic tools can either be applied for
intra vitam or post-mortem diagnostics (Herden et al., 2013).
Intra vitam PDD can be diagnosed by imaging of the gastrointestinal tract (Dennison et al., 2008)
and pathohistological examination of upper gastrointestinal tract biopsies since clinical signs are not
speciﬁc enough and allow many differential diagnoses. Biopsy interpretation is difﬁcult due to the
inconsistent distribution of lesion and only conﬁrmative in case of presence of non-purulent
inﬂammation of ganglia and/or nerves. One study reported false negative results in approximately 24%
(Gregory et al., 1996). Serology for the detection virus speciﬁc antibodies is possible by WB, ELISA and
IFA (de Kloet and Dorrestein, 2009; Lierz et al., 2009; Gray et al., 2010; Herzog et al., 2010;
Villanueva et al., 2010). For IFA, a high sensitivity and speciﬁcity for detection of ABV- speciﬁc serum
antibodies was shown. For virus detection, various RT-PCR assays had to be established due to the
heterogeneity of the viral genotypes/species. Faeces, swabs of crop and cloaca, blood and feather
calami can be used (Lierz et al., 2009; Rinder et al., 2009; Gray et al., 2010; Kistler et al., 2010; de
Kloet et al., 2011). Since shedding of viral RNA can be intermittent and variable organ-wise and the
possible presence of only ABV RNA or ABV–speciﬁc antibodies or both, even in apparently healthy virus
carriers, testing should be repeated and serology and viral RNA detection should be carried out in
parallel (de Kloet and Dorrestein, 2009; Lierz et al., 2009; Herzog et al., 2010; Kistler et al., 2010;
Villanueva et al., 2010; Heffels-Redmann et al., 2012).
Post-mortem, non-purulent (peri)ganglionitis, neuritis mainly in the gastrointestinal tract but also in
other organs, e.g. heart, adrenal gland and encephalitis is quite typical for PDD (Herden et al., 2013).
Viral antigen can be visualised by IHC (Ouyang et al., 2009; Rinder et al., 2009; Herzog et al., 2010;
Raghav et al., 2010; Weissenb€ock et al., 2010; Wunschmann et al., 2011; Piepenbring et al., 2012;
Piepenbring et al., 2016). Viral RNA can be demonstrated by ISH or various RT-PCR assays (see above)
(Honkavuori et al., 2008; Kistler et al., 2008; Rinder et al., 2009; Weissenb€ock et al., 2009; Gray et al.,
2010; Kistler et al., 2010; Lierz et al., 2009; Raghav et al., 2010; Villanueva et al., 2010; Wunschmann
et al., 2011). It should be mentioned, that in birds with PDD, similar presence of histopathological
lesions, viral antigen and RNA can reach up to 100% speciﬁcity and sensitivity (Ouyang et al., 2009;
Weissenb€ock et al., 2009; Raghav et al., 2010; Weissenb€ock et al., 2010; Herzog et al., 2010; Heffels-
Redmann et al., 2011; Wunschmann et al., 2011). Infectious virus can be isolated using avian cell
lines, e.g. quail ﬁbroblasts or skeletal muscles or duck embryo ﬁbroblasts (Rinder et al., 2009; Gray
et al., 2010; Herzog et al., 2010).
Control tools
Parameter 2 – Existence of control tools
There are no ofﬁcial disease control tools for mammalian or avian bornaviruses.
Mammalian bornaviruses (Mammalian 1 bornavirus): Until 2011, there was obligation to
report on cases of Borna disease due to classical infection with BoDV in Germany. However, this was
cancelled in 2011.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
Mammalian bornaviruses (Mammalian 1 bornavirus): Conﬁrmed disease in end hosts such
as horses and sheep have been reported in at least 5 countries (Germany from earliest reports on
around 1890s to date, Switzerland, Austria, Liechtenstein – all since 1970s, the UK (2008) (D€urrwald
et al., 2006; Priestnall et al., 2011).
Avian Bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Presumably present in all Member States
(MS), although no data from all MS are available.
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The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Mammalian bornaviruses (Mammalian 1 bornavirus): In contrast to the seroprevalence in
end/accidental hosts such as horses and sheep, the disease incidence rate is low (see under
Section 3.1.1.2 Parameter 2).
Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Avian bornaviruses have mainly been
described in birds not used for animal production so far.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Transmissibility between animals and humans
Parameter 1 – Types of routes of transmission between animals and humans
Mammalian bornaviruses (Mammalian 2 bornavirus): Unknown so far (see also under
Section 3.1.2.2).
Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Current knowledge does not indicate
zoonotic potential.
Transmissibility between humans
Parameter 3 – Human to human transmission is sufﬁcient to sustain sporadic cases or community-level
outbreak
Mammalian bornaviruses (Mammalian 2 bornavirus): There is no current evidence on
human to human transmission for the novel zoonotic VSBV-1. In humans the infection was neurotropic
which can argue against a possibility of human- human transmission. This resemble closely situation in
naturally infected and diseased end/accidental hosts such as horses (see also under Section 3.1.2.2)
where transmission between horses does not play an important role. However, it should be
emphasised that current knowledge on this novel virus is still sparse.
Parameter 4 – Sporadic, endemic, epidemic, or pandemic potential
Mammalian bornaviruses (Mammalian 2 bornavirus): So far only three documented human
cases infected with the novel bornavirus VSBV-1 exist (Hoffmann et al., 2015).
The severity of human forms of the disease
Parameter 5 – Disability-adjusted life year (DALY)
Mammalian bornaviruses (Mammalian 2 bornavirus): No data.
The availability of effective prevention or medical treatment in humans
Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any
resistance)
Mammalian bornaviruses (Mammalian 2 bornavirus): There is no curative medical treatment
and treatment was only symptomatic in the three human patients, but treatment was not successful
(Hoffmann et al., 2015).
Parameter 7 – Availability of vaccines and their effectiveness (reduced morbidity)
Mammalian bornaviruses (Mammalian 1 bornavirus): For the classical mammalian
bornavirus, a live vaccine for animals existed but was abandoned in 1992, because its efﬁcacy was
questionable (Herden et al., 2013). Moreover, there were concerns on potential viral shedding after
vaccination and establishment of a persistent virus reservoir. Due to the underlying immunopathogenesis
of the clinical disease in end/accidental host, routine vaccination strategies were even more questionable
(Herden et al., 2013). Thus, to date, there is no commercial vaccine available neither for BoDV nor the
novel VSBV-1.
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3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): For the classical mammalian
bornavirus BoDV-1, typically clinical signs progressively worsen within the course of disease of
approximately 1–4 weeks. The case-fatality rate reaches up to 90% in horses (Schmidt, 1952; Grabner
and Fischer, 1991; D€urrwald and Ludwig, 1997; Grabner et al., 2002; Richt et al., 2007). In 72% of
ﬂocks with BD cases, only individual animals develop clinical manifest BD. In cattle and sheep, death
was reported to occur after 1–6 weeks or 1–3 weeks in more than 50% of animals, respectively (Bode
et al., 1994; Richt et al., 1997b).
See also under Section 3.1.1.2 Parameter 2.
Avian bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): As detailed under morbidity, clinical signs in
captive psittacines and non-psittacine birds can vary remarkably with variation in the virus detection
and spread. Severity can range from apparently healthy birds up to sudden death and typical PDD
signs such as gastrointestinal dysfunction and associated wasting with or without neurological signs
(Gregory et al., 1996; Hoppes et al., 2010; Staeheli et al., 2010; Payne et al., 2012; Herden et al.,
2013). In clinical manifest, PDD decreased motility, anorexia, lethargy, undigested seeds in the faeces,
regurgitation, diarrhoea, weight loss resulting in cachexia and vomiting was observed. In cases
exhibiting only neurological signs depression, ataxia, tremor, seizures and motor or proprioceptive
deﬁcits occur. Blindness might occur rarely. Also, in wild birds as shown for example geese, animals
that appear clinically inconspicuous and animals with typical histological lesions can be found (Payne
et al., 2012; Delnatte et al., 2013; Herden et al., 2013).
See also under Section 3.1.1.2 Parameter 2.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): Not known so far.
Avian Bornaviruses (Psittacine bornavirus 1): For example Spix macaw, also known as the
little blue macaw (Cyanopsitta spixii), is a macaw native to Brazil susceptible to Borna virus and listed
as critically endangered species (possibly extinct in the wild) according to IUCN and CITES.
Parameter 2 – Mortality in wild species
Mammalian bornaviruses (Mammalian 1 and 2 bornavirus): There are only few reports
detailing case of death in wild animals, e.g. lynx, deer; infections have been described in animals
originating from the wild and kept in zoos or private husbandries, e.g. vari monkey, alpaca, variegated
squirrel (see also under Section 3.1.1.1) (D€urrwald and Ludwig, 1997; Kinnunen et al., 2007; Payne
et al., 2012; Herden et al., 2013). Reports on naturally infected raccoons and macaques based on
virus speciﬁc serum antibodies and viral RNA detection in the brain only also exist (Hagiwara et al.,
2008; Hagiwara et al., 2009).
Studies in foxes indicate that they can exhibit virus speciﬁc serum antibodies (Bourg et al., 2016) in
contrast to a former report on the presence of viral RNA in foxes (Dauphin et al., 2001).
Avian Bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Most data describe infections and cases of
death in captive birds (see under Section 3.1.1.1). For wild ranging animals, as shown for e.g. geese,
animals that appear clinically inconspicuous can have typical histological lesions (Payne et al., 2012;
Delnatte et al., 2013; Herden et al., 2013). Whether the latter could indicate that wild birds also die
from the infection needs to be further investigated.
See also under Section 3.1.1.1.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
See under Section 3.1.1.5 Parameter 4.
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3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
Not listed.
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
Not listed.
Parameter 3 – Included in any other list of potential bio-agro-terrorism agents
None identiﬁed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Diagnostic tools are detailed under Section 3.1.1.8. The existence of diagnostic and disease control
tools, Diagnostic tools, 1 Existence of diagnostic tools.
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
There are no ofﬁcially certiﬁed tools to date.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
See under Section 3.1.1.8.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
Mammalian bornaviruses (Mammalian 1 bornavirus): For the intra vitam diagnosis of
infection with classical BoDV-1 in BD cases, serum and CSF is needed for the detection of virus speciﬁc
antibodies. For the post-mortem diagnosis of BD, serum and CSF should be tested as well as fresh
frozen samples of brain (nucleus caudatus, hippocampus, cerebral cortex), eye (retina), lacrimal and
parotid gland, trigeminal ganglion, hypophysis and spinal cord for the detection of virus antigen, virus
speciﬁc RNA and infectious virus represent suitable material. Similar tissues should be submitted ﬁxed
in 10% formalin.
Avian Bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): For the intra vitam diagnosis, serum, cloacal
and crop swabs, feather calami as well as biopsies from the upper gastrointestinal tract can be used.
For post-mortem diagnosis, CNS and gastrointestinal tract as well as samples from all other organs
should be sampled and either be fresh frozen or ﬁxed in 10% formalin.
3.1.4.2. Article 7(d)(ii) Vaccination
There is no commercially available vaccine for any mammalian or avian bornaviruses and only
experimental data or older date from vaccination in eastern Germany exists. Due to the viral
persistence with simultaneous presence of high levels of virus-speciﬁc antibodies, humoral immunity
obviously does not play a major role, either for mammalian or avian bornaviruses (Narayan et al., 1983a;
Herzog et al., 1985; Stitz et al., 1989; Heffels-Redmann et al., 2011; Heffels-Redmann et al., 2012;
Piepenbring et al., 2012; Herden et al., 2013; Rubbenstroth et al., 2013; Rubbenstroth et al., 2014a;
Piepenbring et al., 2016).
Mammalian bornaviruses (Mammalian 1 bornavirus): Attenuated virus but not killed
vaccines showed protection experimentally. There was a lapinized live vaccine in eastern Germany,
former GDR which was abandoned in 1992 because its efﬁcacy was questionable (Herden et al.,
2013). Moreover, there were concerns on potential viral shedding after vaccination and establishment
of a persistent virus reservoir. Due to the underlying immunopathogenesis of the clinical disease in
end/accidental host, routine vaccination strategies were even more questionable (Herden et al., 2013).
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High virus titers and induction of a robust T-cell response for mounting an early elimination of the virus
and preventing adverse effects of T-cell-mediated immunopathology seem to be important (Richt
et al., 1994; Oldach et al., 1995; Lewis et al., 1999; Furrer et al., 2001; Stitz et al., 2002; Hausmann
et al., 2005; Henkel et al., 2005). Vector-based vaccines have been used experimentally.
Avian Bornaviruses (Psittacine bornavirus 1 and 2, Passeriform bornavirus 1 and 2,
waterbird 1 bornavirus, unclassiﬁed bornaviruses): Recently, vector-based vaccines have been
generated which might open the avenue for vaccination strategies in the future (Olbert et al., 2016).
3.1.4.3. Article 7(d)(iii) Medical treatments
There are no commercial drugs available on the market neither for mammalian bornaviruses nor avian
bornaviruses. Substances have been tested in vitro or experimentally only, often addressing the viral
strategies to circumvent the antiviral immune response, e.g. interferon system (e.g. interferon-a, -y).
Viral spread could be also efﬁciently inhibited in cell lines and primary CNS cells by an inhibitor against a
host enzyme used by the virus for the cleavage of its glycoprotein (Lennartz et al., 2016).
Mammalian bornaviruses (Mammalian 1 bornavirus): For classical BoDV-1 infections with
BD, the use of amantadine sulfate (AS), a drug with antiviral activity against inﬂuenza A was
recommended but could not be conﬁrmed by others (Herden et al., 2013). Substances such as
ribavirin, Ara-C or 20-ﬂuoro-20-deoxycytidine have been tested in vitro or in animal models with effect
on, e.g. viral transcription or replication, disease outcome (Herden et al., 2013).
Avian bornaviruses (Psittacine bornavirus 1): For avian bornaviruses, interferon-a and
ribavirin could efﬁciently inhibit avian bornaviruses in cell culture, however, there is yet no conﬁrmation
in vivo (Reuter et al., 2010; Reuter et al., 2016; Musser et al., 2015).
In vivo, there is no curative therapy for PDD or ABV infection, and therapy is only symptomatic.
Control of virus infection and prevention could include isolation of ABV-infected birds, sanitation and
disinfection (Hoppes et al., 2010). Control of trafﬁc and trading might further contribute to control viral
spread.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
No available biosecurity measures so far any mammalian or avian bornaviruses.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
No restriction movement measures so far for mammalian or avian bornaviruses.
3.1.4.6. Article 7(d)(vi) Killing of animals
No killing measures for mammalian or avian bornaviruses.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
No speciﬁc disposal options for infected animals available.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
No cost calculations exist so far for mammalian or avian bornaviruses.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Not applicable.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
No control measures anymore; obligation to report on cases of BD in horses was cancelled in
Germany in 2011.
Parameter 2 – Wildlife depopulation as control measure
No control measures for mammalian or avian bornaviruses.
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3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
This is not applicable.
Biodiversity
Parameter 2 – Mortality in wild species
See under Section 3.1.1.1.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about Borna disease (Table 1). The expert judgement was based on Individual and Collective
Behavioural Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA
AHAW Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped
into Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N
or ‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 11. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Table 2). The proportion of Y, N or na answers are reported, followed by
the list of different supporting views for each answer.
Table 1: Outcome of the expert judgement on the Article 5 criteria for Borna disease
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist
in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
NC
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
N
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
N
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
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Reasoning supporting the judgement
Supporting Yes:
• For VSBV-1, a zoonotic potential has been demonstrated.
• Borna disease can cause negative effects (mortality) on animals, particularly in mammals, e.g.
in horses but also in cattle and sheep.
• Supporting No:
• Mostly a clinically inapparent infection and very few animals present with clinical signs (< 0.1%
horses and < 0.01% sheep in endemic areas). Prognosis is poor for cases with clinical signs.
• The virus and antibodies can be detected, but often without clinical signs.
• Only novel recently identiﬁed bornavirus VSBV from asymptomatic captive variegated squirrels
is conﬁrmed as zoonotic, but the transmission route is not certain, suspected by very close
contact with possibly intranasal transmission, bites or scratches.
3.2.2. Outcome of the assessment of Borna disease according to criteria of
Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 1, BD does not
comply with criterion A(v) and the assessment is inconclusive on compliance with criterion 5 A(iii).
Therefore, BD cannot be considered eligible to be listed for Union intervention as laid down in Article 5
(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about Borna disease (Tables 3, 4, 5, 6 and 7). The expert
judgement was based on ICBA approach described in detail in the opinion on the methodology.
Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria
(see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement
on each criterion of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 11. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 2: Outcome of the expert judgement related to criterion 5 A(iii)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
A(iii) The disease causes negative effects on animal health or
poses a risk to public health due to its zoonotic character
NC 36 64 0
NC: non-consensus; number of judges: 11.
Table 3: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for Borna disease (CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory
of the Union
NC
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread NC
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
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At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4 (PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 4: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for Borna disease (CI = current impact; PI = potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free
of the disease
N
2.1 The disease is moderately to highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread NC
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4 (CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4 (PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
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5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 5: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for Borna disease (CI=current impact; PI=potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
NC
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 8, 9 and
10). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting
views for each answer.
Reasoning supporting the judgement
Supporting Yes for 1 (cat.A):
• There are only very limited endemic areas in four MSs, namely speciﬁc regions in Germany,
Austria, Switzerland and Liechtenstein, where clinically apparent classical BDV-1 occurs and
where endemic viral clusters with a strong geographical association have been reported being
related to the occurrence of the viral reservoir.
Supporting Yes for 1 (cat.C):
• There are no ofﬁcially free areas, but information about the distribution of Borna viruses is
limited since no surveillance is in place in Europe.
• Presumably it is endemic in all MSs due to avian Borna viruses, although data are sparse.
• In MSs where surveys were initiated, seropositive cases have been detected.
Table 6: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for Borna disease
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
N
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 7: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for Borna disease
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
N
Colour code: green = consensus (Yes/No).
Table 8: Outcome of the expert judgement related to criterion 1 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
1(cat.A) The disease is not present in the territory of the Union OR present
only in exceptional cases (irregular introductions) OR present in
only in a very limited part of the territory of the Union
NC 9 91 0
1(cat.C) The disease is present in the whole OR part of the Union territory
with an endemic character
NC 91 9 0
NC: non-consensus; number of judges: 11.
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Reasoning supporting the judgement
Supporting Yes:
• The rate of transmission is actually unknown, although the disease is endemic in certain areas,
thus the infection is expected to spread over with a reproductive ratio of at least 1.
Supporting na:
• The incidence and speed of transmission is unknown and no data are available even within the
known reservoir species. At times, only single animals present with manifest disease.
• Even in stables with an endemic problem, there are antibody-negative animals.
• No data are available, but apparently the transmission rate seems neither high nor moderate.
Reasoning supporting the judgement
Supporting No:
• Airborne, waterborne or vector-borne spread has never been described for BD. Based on
information presented in the fact sheet, there is not such kind of spread. Since the virus shed
in secretions, excretions, urine and faeces, the most likely transmission route is via direct
contact, inhalation or via the orofaecal route.
Supporting na:
• Suspected routes of transmission are described but not proven. No evidence is presented
supporting or ruling out airborne, waterborne or vector-borne transmission and there is still
much unknown about the nature and rate of transmission.
3.3.2. Outcome of the assessment of criteria in Annex IV for Borna disease for
the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for Borna disease for the
purpose of categorisation as in Article 9 of the AHL is presented in Table 11.
Table 10: Outcome of the expert judgement related to criterion 2.2 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
2.2 There be possibilities of airborne or waterborne or
vector-borne spread
NC 0 73 27
NC: non-consensus; number of judges: 11.
Table 9: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
2.1(cat.B,C) The disease is moderately to highly transmissible NC 55 0 45
NC: non-consensus; number of judges: 11.
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According to the assessment here performed, BD complies with the following criteria of the
Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BD complies only with criterion 2.3, but not
with 2.1 and 2.4, and the assessment is inconclusive on compliance with criterion 1 and 2.2.
To be eligible for category A, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and BD does not comply with any criteria.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BD complies only with criterion 2.3, but not
with 1 and 2.4, and the assessment is inconclusive on compliance with criterion 2.1 and 2.2.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and BD does not comply with any criteria.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BD complies with criteria 2.2 and 2.3, but not
with 2.4, and the assessment is inconclusive on the compliance with criteria 1 and 2.1. To be
eligible for category C, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and BD does not comply with any criteria.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL, and with the speciﬁc criterion D of Section 4, with which BD does
not comply.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5 with which BD does not
comply.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
BD. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
Table 11: Outcome of the assessment of criteria in Annex IV for Borna disease for the purpose of
categorisation as in Article 9 of the AHL (CI = current impact; PI = potential impact)
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Article 9 criteria
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a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.1 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for Borna disease according to the
criteria of Article 8(3) of the AHL are as displayed in Table 12.
Table 12: Main animal species to be listed for Borna disease according to criteria of Article 8
(source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Aves Accipitriformes Accipitridae Bald eagle (Haliaeetus leucocephalus)
Anseriformes Anatidae Northern pintail (Anas acuta), gadwall (Anas
strepera), mallard (Anas plytyrhynchos),
Canada goose(Branta Canadensis),
Trumpeter swan (Cygnus Cygnus
buccinators), mute swan (Cygnus olor)
Charadriiformes Charadriidae Not speciﬁed
Columbiformes Columbidae Pigeons (not speciﬁed)
Galliformes Phasianidae Gallus gallus
Gruiformes Gruidae Cranes (not speciﬁed)
Emberizidae Not speciﬁed
Estrildidae Munia (not speciﬁed), ﬁnches
(not speciﬁed)
Fringillidae Canaries (not speciﬁed)
Psittaciformes Cacatuidae Cockatoos (not speciﬁed)
Psittacidae African grey parrots (Psittacus erithacus),
Patagonian conure (Cyanoliseus patagonus),
Psitacinae (not speciﬁed)
Mammalia Artiodactyla Bovidae Domestic cattle (Bos taurus), domestic goat
(Capra aegagrus), domestic sheep (Ovis
aries)
Camelidae Alpaca (Vicugna pacos)
Cervidae Deer (not speciﬁed)
Hippopotamidae Hippopotamus (Hippopotamus amphibius)
Carnivora Canidae Domestic dog (Canis familiaris), foxes
(Vulpes vulpes)
Felidae Domestic cat (Felis catus), lynx (not
speciﬁed)
Mustelidae Ferret (Mustela putorius furo), badger
(Meles meles)
Procyonidae Racoon (Procyon lotor)
Chiroptera Not speciﬁed
Lagomorpha Leporidae Domestic rabbit (Oryctolagus cuniculus)
Perissodactyla Equidae Domestic horse (Equus caballus)
Rhinocerotidae Great Indian rhinoceros (Rhinoceros
unicorni)
1 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, BD does not comply with criterion 5 A(v) of the
ﬁrst set and therefore cannot be considered eligible to be listed for Union intervention as laid
down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, since BD cannot be considered eligible to be
listed for Union intervention as laid down in Article 5(3) of the AHL, the assessment of its
compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation
of diseases in accordance with Article 9 of the AHL is not applicable.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, since BD cannot be considered eligible to be
listed for Union intervention as laid down in Article 5(3) of the AHL, there are no animal
species that can be considered to be listed for BD according to Article 8(3) of the AHL.
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ABBV aquatic bird bornavirus
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AHL Animal Health Law
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BD Borna disease
BDV Borna disease virus
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